How India Exports Ornidazole to the World

As of March 2026, Ornidazole does not have any approved Abbreviated New Drug Applications (ANDAs) listed in the FDA's Orange Book. This absence suggests that Ornidazole has not been granted marketing authorization in the United States. Consequently, Indian exporters aiming to penetrate the U.S. market must navigate the FDA's rigorous regulatory framework, which includes submitting a New Drug Application (NDA) or ANDA, demonstrating bioequivalence, and adhering to Good Manufacturing Practices (GMP). Given the current exporter count and the absence of U.S. approvals, strategic planning and substantial investment in regulatory compliance are imperative for market entry.

In the European Union, medicinal products like Ornidazole require a marketing authorization from the European Medicines Agency (EMA) or the respective national competent authorities. The authorization process mandates comprehensive data on quality, safety, and efficacy. Additionally, compliance with EU Good Manufacturing Practice (GMP) standards is essential. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the authorization process, which mirrors the EU's stringent requirements. Notably, France, accounting for 19.7% of India's Ornidazole exports, necessitates adherence to these regulatory standards, underscoring the importance of compliance for market access.

Ornidazole is not listed in the World Health Organization's (WHO) Model List of Essential Medicines as of the latest edition. Consequently, it has not undergone the WHO Prequalification of Medicines Programme, which assesses the quality, safety, and efficacy of medicinal products. For international acceptance, Ornidazole formulations must comply with pharmacopoeial standards such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Adherence to these standards ensures product quality and facilitates global market acceptance.

In India, Ornidazole is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription-only medication. As of March 2026, Ornidazole is not listed under the Drug Price Control Order (DPCO) by the National Pharmaceutical Pricing Authority (NPPA), meaning it is not subject to government-mandated price ceilings. For export purposes, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and facilitating international trade.

Ornidazole's primary patents have expired, leading to the availability of generic versions in various markets. This expiration has intensified competition among manufacturers and exporters. However, the absence of FDA approval in the U.S. market indicates potential opportunities for Indian exporters willing to invest in the necessary regulatory approvals to gain market access.

In June 2025, the Indian Ministry of Health and Family Welfare revised the export NOC requirements, streamlining the process for pharmaceutical products, including Ornidazole, thereby facilitating faster export approvals.

In September 2025, the European Medicines Agency (EMA) updated its GMP guidelines, emphasizing stricter compliance measures for active pharmaceutical ingredients (APIs). Indian manufacturers exporting to the EU, particularly to France, which accounts for 19.7% of Ornidazole exports, must align with these enhanced standards to maintain market access.

In December 2025, the World Health Organization (WHO) released a new edition of the Model List of Essential Medicines. Ornidazole was not included, indicating that while it remains a valuable therapeutic agent, it does not meet the current criteria for essential medicines designation.

In February 2026, the Indian Pharmacopoeia Commission (IPC) updated the monograph for Ornidazole, incorporating revised analytical methods to ensure better quality control. Manufacturers are advised to adopt these methods to comply with national standards.

In March 2026, the U.S. Food and Drug Administration (FDA) issued a draft guidance on the development of nitroimidazole derivatives, including Ornidazole, outlining the necessary clinical and non-clinical data requirements for potential approval. This guidance provides a clearer pathway for Indian exporters considering entry into the U.S. market.

These developments underscore the dynamic nature of the pharmaceutical regulatory landscape and the importance of continuous monitoring to ensure compliance and strategic market positioning.

Ornidazole, an antibiotic primarily produced in India, relies heavily on Key Starting Materials (KSMs) sourced from China. This dependency is part of a broader trend where approximately 70% of India's APIs are imported from China, as noted in a June 2024 report. Such reliance exposes the supply chain to vulnerabilities, especially when Chinese manufacturers face operational disruptions. For instance, in 2024, environmental regulations led to the shutdown of numerous Chinese API producers, causing significant supply constraints and price escalations for Indian pharmaceutical companies.

To mitigate these risks, the Indian government initiated the Production Linked Incentive (PLI) scheme in February 2021, aiming to bolster domestic production of critical APIs and KSMs. By November 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and 6-APA, marking a significant step toward reducing import dependence. However, the effectiveness of these measures in fully addressing the supply chain vulnerabilities remains to be seen.

Our proprietary trade data from 2022 to 2026 indicates that the top five exporters of Ornidazole from India account for 64.3% of the total export value, with LINCOLN PHARMACEUTICALS LTD alone contributing 29.5%. This high supplier concentration poses a significant risk, as any disruption affecting these key players could severely impact global supply chains.

The PLI scheme, launched in February 2021, aims to diversify and strengthen the supplier base by incentivizing domestic production of APIs and KSMs. While this initiative has led to the establishment of new manufacturing units, the transition to a more diversified supplier landscape is ongoing and requires sustained efforts.

The global pharmaceutical supply chain is susceptible to geopolitical tensions and shipping disruptions. Incidents such as the Red Sea crisis and Strait of Hormuz tensions have previously led to shipping diversions, increased costs, and insurance premium adjustments. In February 2026, the Indian Ministry of Commerce & Industry convened a high-level consultation to assess these risks and safeguard India's export-import supply chains.

Additionally, the U.S. Food and Drug Administration (FDA) has issued alerts regarding drug shortages linked to supply chain disruptions, underscoring the global impact of such events. These challenges highlight the need for robust risk management strategies to ensure the uninterrupted supply of essential medicines like Ornidazole.

• Diversify Supplier Base: Encourage the development of alternative suppliers for Ornidazole and its KSMs to reduce dependency on a limited number of exporters and source countries.

• Enhance Domestic Production: Accelerate the implementation of the PLI scheme to boost local manufacturing capabilities for APIs and KSMs, thereby decreasing reliance on imports.

• Strengthen Regulatory Compliance: Ensure that domestic manufacturers adhere to stringent environmental and quality standards to prevent operational disruptions similar to those experienced by Chinese suppliers.

• Develop Strategic Reserves: Establish stockpiles of critical APIs and KSMs to buffer against short-term supply chain disruptions caused by geopolitical events or natural disasters.

• Implement Advanced Monitoring Systems: Utilize real-time data analytics to monitor global supply chain dynamics, enabling proactive responses to potential disruptions.

RISK_LEVEL: MEDIUM